Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02023905 : Everolimus With and Without Temozolomide in Adult Low Grade Glioma
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Age = 18 years

- KPS = 60

- Adequate bone marrow function as shown by: ANC = 1.5 x 10^9/L, Platelets = 100 x
10^9/L, Hb = 9.0 g/dL;

- Adequate liver function as shown by: Total serum bilirubin = 2.0 mg/dL, ALT and AST =
2.5x ULN, INR = 2;

- Adequate renal function: serum creatinine =1.5 x ULN;

- Fasting serum cholesterol = 300 mg/dL OR = 7.75 mmol/L AND fasting triglycerides =
2.5x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can
only be included after initiation of appropriate lipid lowering medication with
confirmed reduction of lab values to within eligibility parameters;

- Signed informed consent prior to any screening procedures

- Histologically proven supratentorial low-grade glioma at initial diagnosis; pathology
must have been reviewed by UCSF neuropathology. Eligible low-grade gliomas include:
astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Pilocytic astrocytomas are

- Patient's tumor must have documentation of the presence of an IDH-1 and/or IDH-2
mutation of any type.

- Results of 1p/19q chromosomal status and pPRAS40 testing must be available to permit
treatment selection.

- Evaluable disease

- Must begin treatment within 120 days of surgical procedure

Exclusion Criteria:

- No prior tumor treatment except for surgery at diagnosis, and must have adequately
recovered from surgery

- Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g.
sirolimus, temsirolimus) or to temozolomide

- Known impairment of gastrointestinal (GI) function or GI disease that may
significantly alter the absorption of oral everolimus or temozolomide

- Uncontrolled diabetes mellitus as defined by HbA1c > 8.0% despite adequate therapy.
Patients with a known history of impaired fasting glucose or diabetes mellitus (DM)
may be included, however blood glucose and antidiabetic treatment must be monitored
closely throughout the trial and adjusted as necessary;

- Any severe and/or uncontrolled medical conditions such as: unstable angina pectoris,
symptomatic congestive heart failure, myocardial infarction =6 months prior to start
of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically
significant cardiac disease; symptomatic congestive heart failure of New York heart
Association Class III or IV; active (acute or chronic) or uncontrolled severe
infection, liver disease such as cirrhosis, decompensated liver disease, and chronic
hepatitis (i.e. quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA);
known severely impaired lung function (spirometry and DLCO 50% or less of normal and
O2 saturation 88% or less at rest on room air); active, bleeding diathesis;

- Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or
inhaled corticosteroids are allowed, and treatment with low dose Decadron (= 3mg
daily) is allowed;

- Known history of HIV seropositivity;

- Positive serological test results for hepatitis B

- Positive serological test result for hepatitis C

- Recipients of live attenuated vaccines within 1 week of start of treatment and during
the study. Avoid close contact with others who have received live attenuated vaccines.
Examples of live attenuated vaccines include intranasal influenza, measles, mumps,
rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;

- History of another primary malignancy, with the exceptions of: non-melanoma skin
cancer, and carcinoma in situ of the cervix, uterus, or breast, unless the patient has
been disease free for = 3 years;

- History of non-compliance to medical regimens or who are considered potentially
unreliable or will not be able to complete the entire study;

- Currently part of or have participated in any clinical investigation with an
investigational therapeutic drug within 1 month prior to dosing;

- Pregnant or nursing (lactating) women;

- Women of child-bearing potential (WOCBP), defined as all women physiologically capable
of becoming pregnant, who are not willing to use adequate methods of contraception
during the study and for 8 weeks after the end of treatment.

- Women are considered post-menopausal and not of child-bearing potential if they have
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
(e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral
oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior
to randomization. In the case of oophorectomy alone, only when the reproductive status
of the woman has been confirmed by follow up hormone level assessment is she
considered not of child-bearing potential.

- Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate
contraception, during the study and for 8 weeks after the end of treatment
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557